Cited by 379Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

Open access

Natali, A., Ferrannini, E.·2006·Diabetologia

DOI 10.1007/s00125-006-0141-7

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis Insulin resistance, which manifests itself as endogenous glucose overproduction and reduced insulin-mediated glucose uptake, is a core defect in type 2 diabetes. Metformin and the peroxisome proliferator-activated receptor-gamma agonists, the thiazolidinediones (TZDs), both lower glucose, although their mechanism of action is still subject to debate. This review analyses the evidence relevant to these mechanisms in vivo.Materials and methods A systematic search of MEDLINE identified a total of 42 clinical studies that investigated the effects of TZDs (n=23) and/or metformin (n=19) on endogenous glucose production (using tracer glucose techniques) and peripheral glucose disposal (using the euglycaemic-hyperinsulinaemic clamp) in patients with type 2 diabetes (n=549). The original variables assessed were converted into standardised units and their mean group values were listed separately for open and placebo-controlled studies. Statistical analysis was scarried out, treating mean group values as individual values and comparing results (both as absolute values and percentage changes from baseline) across study categories (open vs placebo-controlled, TZDs vs metformin).Results Both TZDs and metformin enhance insulin suppression of endogenous glucose production and fasting plasma glucose clearance. TZDs, but not metformin, also improve insulin-mediated glucose uptake at all insulin levels.Conclusions/interpretation In patients with type 2 diabetes, metformin improves fasting hepatic insulin sensitivity and glucose clearance; TZDs improve fasting hepatic insulin sensitivity and glucose clearance, and potentiate glucose disposal under insulinised conditions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-006-0141-7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B. H., Beerdsen, P., Joyce, M., & Olefsky, J. M. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 914
Insulin resistance and hypersecretion in obesity: European Group for the Study of Insulin Resistance (EGIR)
Ferrannini, E., Natali, A., Bell, P., Cavallo-Perin, P., Lalic, N., & Mingrone, G. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119628 · Cited by 898 · cited 1×
“concentrations (European Group for the study of Insulin Resistance [EGIR] database [18]).”
BackgroundSelf-citation
Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus
Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794
International Textbook of Diabetes Mellitus
(2003) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 744
Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists
Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10843 · Cited by 536
The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488
Metformin
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 315
Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
Schernthaner, G., Matthews, D. R., Charbonnel, B. H., Hanefeld, M., & Brunetti, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030861 · Cited by 267
Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes
Tonelli, J., Li, W., Kishore, P., Pajvani, U. B., Kwon, E., Weaver, C. L., Scherer, P. E., & Hawkins, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1621 · Cited by 247
Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells
Hundal, H. S., Ramlal, T., Reyes, R., Leiter, L. A., & Klip, A. (1992) · Endocrinology · doi:10.1210/endo.131.3.1505458 · Cited by 243

Show all 32 references

Sorted by citations

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus.
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Metformin: from mechanisms of action to therapies
Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.09.018 · Cited by 1,501
Oral Antidiabetic Agents
Thomas, N., Senthil, K., & Kapoor, N. (2016) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/12651_7 · Cited by 943
Type 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin
Fullerton, M. D., Galic, S., Marcinko, K., Sikkema, S., Pulinilkunnil, T., Chen, Z.-P., O'Neill, H. M., Ford, R. J., Palanivel, R., O'Brien, M., et al. (2013) · Nature Medicine · doi:10.1038/nm.3372 · Cited by 893
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686
AMPK as a Therapeutic Target for Treating Metabolic Diseases
Day, E. A., Ford, R. J., & Steinberg, G. R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.05.004 · Cited by 630
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes
Soccio, R. E., Chen, E. R., & Lazar, M. A. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.08.005 · Cited by 518
Metformin pathways: pharmacokinetics and pharmacodynamics
Gong, L., Goswami, S., Giacomini, K. M., Altman, R. B., & Klein, T. E. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283559b22 · Cited by 495
From pre-diabetes to diabetes: diagnosis, treatments and translational research
Khan, R., Chua, Z., Tan, J., Yang, Y., Liao, Z., & Zhao, Y. (2019) · Medicina · doi:10.3390/medicina55090546 · Cited by 484
Long-term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients With Type 2 Diabetes Mellitus
Kooy, A., de Jager, J., Lehert, P., Bets, D., Wulffelé, M. G., Donker, A. J. M., & Stehouwer, C. D. A. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.20 · Cited by 440
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Hawley, S. A., Ford, R. J., Smith, B. K., Gowans, G. J., Mancini, S. J., Pitt, R. D., Day, E. A., Salt, I. P., Steinberg, G. R., & Hardie, D. G. (2016) · Diabetes · doi:10.2337/db16-0058 · Cited by 401
The role of α-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, J. W., Konopski, Z., Eggesbø, H. B., von Volkmann, H. L., Raschpichler, G., Bjøro, K., Haaland, T., Løberg, E. M., & Birkeland, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902845268 · Cited by 323
Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 324
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 323
Hypothalamic AMPK: a canonical regulator of whole-body energy balance
López, M., Nogueiras, R., Tena‐Sempere, M., & Diéguez, C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.67 · Cited by 318
Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier
Divakaruni, A. S., Wiley, S. E., Rogers, G. W., Andreyev, A. Y., Petrosyan, S., Loviscach, M., Wall, E. A., Yadava, N., Heuck, A. P., Ferrick, D. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303360110 · Cited by 308
Metformin Activates AMP-Activated Protein Kinase in Primary Human Hepatocytes by Decreasing Cellular Energy Status
Stephenne, X., Foretz, M., Taleux, N., van der Zon, G. C., Sokal, E., Hue, L., Viollet, B., & Guigas, B. (2011) · Diabetologia · doi:10.1007/s00125-011-2311-5 · Cited by 287
Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention
Gottwald‐Hostalek, U., Gwilt, M., & Hildemann, S. K. (2015) · Drugs · doi:10.1007/s40265-015-0416-8 · Cited by 283
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic Disorders
Januś, A., Szahidewicz-Krupska, E., Mazur, G. J., & Doroszko, A. (2016) · Mediators of Inflammation · doi:10.1155/2016/3634948 · Cited by 277
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 265
Self-citation
Insulin resistance and insulin sensitizing agents
Mastrototaro, L., & Roden, M. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154892 · Cited by 274
The metabolism of proline, a stress substrate, modulates carcinogenic pathways
Phang, J. M., Donald, S. P., Pandhare, J., & Liu, Y. (2008) · Amino Acids · doi:10.1007/s00726-008-0063-4 · Cited by 252
Metformin, the Aspirin of the 21st Century: Its Role in Gestational Diabetes Mellitus, Prevention of Preeclampsia and Cancer, and the Promotion of Longevity
Romero, R., Erez, O., Hüttemann, M., Maymon, E., Panaitescu, B., Conde-Agudelo, A., Pacora, P., Yoon, B. H., & Grossman, L. I. (2017) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2017.06.003 · Cited by 253
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome
Diamanti‐Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 251
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 218
Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects
Kusuhara, H., Ito, S., Kumagai, Y., Jiang, M., Shiroshita, T., Moriyama, Y., Inoue, K., Yuasa, H., & Sugiyama, Y. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.36 · Cited by 218
Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects
Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 216
Metformin Effects on the Heart and the Cardiovascular System: A Review of Experimental and Clinical Data
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211
Self-citation
Resveratrol ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice
Zhang, H., Zhai, Z., Wang, Y., Zhang, J., Wu, H., Wang, Y., Li, C., Li, D., Lu, L., Wang, X., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.530 · Cited by 212
Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study
Zhou, K., Donnelly, L. A., Kimber, C. H., Donnan, P. T., Doney, A. S. F., Leese, G., Hattersley, A. T., McCarthy, M. I., Morris, A. D., Palmer, C. N. A., et al. (2009) · Diabetes · doi:10.2337/db08-0896 · Cited by 190
The effects of metformin on autophagy
Lu, G., Wu, Z., Shang, J., Xie, Z., Chen, C., & zhang, C. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111286 · Cited by 188
The Metabolism of Proline as Microenvironmental Stress Substrate
Phang, J. M., Pandhare, J., & Liu, Y. (2008) · Journal of Nutrition · doi:10.1093/jn/138.10.2008s · Cited by 175
The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective
Agius, L., Ford, B. E., & Chachra, S. S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093240 · Cited by 183
Metformin Lowers Plasma Triglycerides by Promoting VLDL-Triglyceride Clearance by Brown Adipose Tissue in Mice
Geerling, J. J., Boon, M. R., van der Zon, G. C., van den Berg, S. A. A., van den Hoek, A. M., Lombès, M., Princen, H. M. G., Havekes, L. M., Rensen, P. C. N., & Guigas, B. (2013) · Diabetes · doi:10.2337/db13-0194 · Cited by 173
Enhancement of Muscle Mitochondrial Oxidative Capacity and Alterations in Insulin Action Are Lipid Species Dependent
Turner, N. A., Hariharan, K., Tid-Ang, J. D., Frangioudakis, G., Beale, S. M., Wright, L. E., Zeng, X., Leslie, S. J., Li, J.-Y., Kraegen, E. W., et al. (2009) · Diabetes · doi:10.2337/db09-0784 · Cited by 162
Metformin and salicylate synergistically activate liver AMPK, inhibit lipogenesis and improve insulin sensitivity
Ford, R. J., Fullerton, M. D., Pinkosky, S. L., Day, E. A., Scott, J. W., Oakhill, J. S., Bujak, A. L., Smith, B. K., Crane, J. D., Blümer, R. M. E., et al. (2015) · Biochemical Journal · doi:10.1042/bj20150125 · Cited by 164
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 173
The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus
Lee, C. B., Chae, S. U., Jo, S. J., Jerng, U. M., & Bae, S. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073566 · Cited by 151
Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes
Ahren, B. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s33934 · Cited by 148
Metformin and other antidiabetic agents in renal failure patients
Lalau, J., Arnouts, P., Sharif, A., & Broe, M. E. D. (2014) · Kidney International · doi:10.1038/ki.2014.19 · Cited by 147
Metformin, cancer and glucose metabolism
Salani, B., Río, A. D., Marini, C., Sambuceti, G., Cordera, R., & Maggi, D. C. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0284 · Cited by 129
Offsetting the impact of smoking and e-cigarette vaping on the cerebrovascular system and stroke injury: Is Metformin a viable countermeasure?
Kaisar, M. A., Villalba, H., Prasad, S., Liles, T., Sifat, A. E., Sajja, R. K., Abbruscato, T. J., & Cucullo, L. (2017) · Redox Biology · doi:10.1016/j.redox.2017.06.006 · Cited by 128
In Vivo Actions of Peroxisome Proliferator–Activated Receptors
Eldor, R., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2003 · Cited by 128
Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice
Xu, G., Wu, H., Zhang, J., Li, D., Wang, Y., Wang, Y., Zhang, H., Lu, L., Li, C., Huang, S. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.05.045 · Cited by 132
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system
Hasan, A. A., Madkor, H., & Wageh, S. (2013) · Drug Delivery · doi:10.3109/10717544.2013.779332 · Cited by 122
Measurements of Islet Function and Glucose Metabolism with the Dipeptidyl Peptidase 4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes
Azuma, K., Rádiková, Ž., Mancino, J., Toledo, F. G. S., Thomas, E., Kangani, C. O., Man, C. D., Cobelli, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1369 · Cited by 121
Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma
Sauer, S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.010 · Cited by 122
Pleiotropic effects of metformin: Shaping the microbiome to manage type 2 diabetes and postpone ageing
Prattichizzo, F., Giuliani, A., Mensa’, E., Sabbatinelli, J., Nigris, V. D., Rippo, M. R., Sala, L. L., Procopio, A. D., Olivieri, F., & Ceriello, A. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.003 · Cited by 114
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
Mallewa, J. E., Wilkins, E., Vilar, J., Mallewa, M., Doran, D. A., Back, D. J., & Pirmohamed, M. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn251 · Cited by 109
Clinical utility of metabolic syndrome severity scores: considerations for practitioners
DeBoer, M. D., & Gurka, M. J. (2017) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s101624 · Cited by 113
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 101
Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes
Cree-Green, M., Bergman, B. C., Cengiz, E., Fox, L. A., Hannon, T. S., Miller, K., Nathan, B., Pyle, L., Kahn, D., Tansey, M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00129 · Cited by 101
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
Schernthaner, G., Currie, C. J., & Schernthaner, G.-H. (2013) · Diabetes Care · doi:10.2337/dcs13-2031 · Cited by 100
Discovery of Potent and Specific Fructose-1,6-Bisphosphatase Inhibitors and a Series of Orally-Bioavailable Phosphoramidase-Sensitive Prodrugs for the Treatment of Type 2 Diabetes
Dang, Q., Kasibhatla, S. R., Reddy, K. R., Jiang, T., Reddy, M. R., Potter, S. C., Fujitaki, J. M., van Poelje, P. D., Huang, J., Lipscomb, W. N., et al. (2007) · Journal of the American Chemical Society · doi:10.1021/ja074871l · Cited by 103
Metformin in Reproductive Biology
Faure, M., Bertoldo, M. J., Khoueiry, R., Bongrani, A., Brion, F., Giulivi, C., Dupont, J., & Froment, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00675 · Cited by 103
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact
Phielix, E., Szendroedi, J., & Roden, M. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.06.006 · Cited by 92
Polycystic ovary syndrome in adolescents
Rothenberg, S. S., Beverley, R. M., Barnard, E., Baradaran-Shoraka, M., & Sanfilippo, J. S. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2017.08.008 · Cited by 88
Mechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 89
Pioglitazone for type 2 diabetes mellitus
Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., & Ebrahim, S. H. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006060.pub2 · Cited by 87
Low metformin causes a more oxidized mitochondrial NADH/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism
Alshawi, A., & Agius, L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006670 · Cited by 87
Bone health in diabetes and prediabetes
Costantini, S., & Conte, C. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.421 · Cited by 84
General aspects of muscle glucose uptake
Alvim, R. D. O., CHEUHEN, M. R., MACHADO, S. R., de Sousa, A. G. P., & SANTOS, P. C. J. L. (2015) · Anais da Academia Brasileira de Ciências · doi:10.1590/0001-3765201520140225 · Cited by 92
Immunometabolism of T cells and NK cells: metabolic control of effector and regulatory function
Poznanski, S. M., Barra, N. G., Ashkar, A. A., & Schertzer, J. D. (2018) · Inflammation Research · doi:10.1007/s00011-018-1174-3 · Cited by 78
The Importance of Mitochondrial Pyruvate Carrier in Cancer Cell Metabolism and Tumorigenesis
Ruiz-Iglesias, A., & Mañes, S. (2021) · Cancers · doi:10.3390/cancers13071488 · Cited by 83
GPD1 Enhances the Anticancer Effects of Metformin by Synergistically Increasing Total Cellular Glycerol-3-Phosphate
Xie, J., Ye, J., Cai, Z., Luo, Y., Zhu, X., Deng, Y., Feng, Y., Liang, Y., Liu, R., Han, Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2852 · Cited by 75
Differential Effects of Krill Oil and Fish Oil on the Hepatic Transcriptome in Mice
Burri, L., Berge, K., Wibrand, K., Berge, R. K., & Barger, J. L. (2011) · Frontiers in Genetics · doi:10.3389/fgene.2011.00045 · Cited by 73
The radioprotective effect of metformin against cytotoxicity and genotoxicity induced by ionizing radiation in cultured human blood lymphocytes
Cheki, M., Shirazi, A., Mahmoudzadeh, A., Bazzaz, J. T., & Hosseinimehr, S. J. (2016) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2016.09.001 · Cited by 72
AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
Lu, Q., Li, X., Liu, J., Sun, X., Rousselle, T., Ren, D., Tong, N., & Li, J. (2019) · Bioscience Reports · doi:10.1042/bsr20181995 · Cited by 69
Revisiting the mechanisms of metformin action in the liver
Viollet, B., & Foretz, M. (2013) · Annales d Endocrinologie · doi:10.1016/j.ando.2013.03.006 · Cited by 70
miR-378a: a new emerging microRNA in metabolism
Machado, I. F., Teodoro, J. S., Palmeira, C. M., & Rolo, A. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03375-z · Cited by 72
A Randomised, Double-Blind, Placebo-Controlled Trial of Metformin on Myocardial Efficiency in Insulin-Resistant Chronic Heart Failure Patients without Diabetes
Larsen, A. H., Jessen, N., Nørrelund, H., Tolbod, L. P., Harms, H. J., Feddersen, S., Nielsen, F., Brøsen, K., Hansson, N. H., Frøkiær, J., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1656 · Cited by 69
Effect of Pioglitazone on the Metabolic and Hormonal Response to a Mixed Meal in Type II Diabetes
Gastaldelli, A., Casolaro, A., Pettiti, M., Nannipieri, M., Ciociaro, D., Frascerra, S., Buzzigoli, E., Baldi, S., Mari, A., & Ferrannini, E. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100034 · Cited by 68
Self-citation
Cardiovascular safety of anti-diabetic drugs
Kumar, R. B., Kerins, D. M., & Walther, T. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv035 · Cited by 67
Gut Hormone Pharmacology of a Novel GPR119 Agonist (GSK1292263), Metformin, and Sitagliptin in Type 2 Diabetes Mellitus: Results from Two Randomized Studies
Nunez, D. J., Bush, M., Collins, D. A., McMullen, S. L., Gillmor, D., Apseloff, G., Atiee, G. J., Corsino, L., Morrow, L., & Feldman, P. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092494 · Cited by 65
Metformin increases endogenous glucose production in non-diabetic individuals and individuals with recent-onset type 2 diabetes
Gormsen, L. C., Søndergaard, E., Christensen, N. L., Brøsen, K., Jessen, N., & Nielsen, S. (2019) · Diabetologia · doi:10.1007/s00125-019-4872-7 · Cited by 63
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
Abdul-Ghani, M. A., & DeFronzo, R. A. (2017) · Diabetes Care · doi:10.2337/dc16-2368 · Cited by 64
Metformin promotes autophagy in ischemia/reperfusion myocardium via cytoplasmic AMPKα1 and nuclear AMPKα2 pathways
Wang, Y., Yang, Z., Zheng, G., Yu, L., Yin, Y., Mu, N., & Ma, H. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.002 · Cited by 63
Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes
Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., & Rizza, R. A. (2008) · Diabetes · doi:10.2337/db07-0827 · Cited by 63
Hesperidin prevents hyperglycemia in diabetic rats by activating the insulin receptor pathway
Peng, P., Jin, J., Zou, G., Sui, Y.-B., Han, Y., Zhao, D., & Liu, L. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9485 · Cited by 65
Adult-onset autoimmune diabetes
Buzzetti, R., Maddaloni, E., Gaglia, J. L., Leslie, R. D., Wong, F. S., & Boehm, B. O. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00390-6 · Cited by 70
The Effect of Pioglitazone and Metformin on Liver Function Tests, Insulin Resistance, and Liver Fat Content in Nonalcoholic Fatty Liver Disease: A Randomized Double Blinded Clinical Trial
Razavizade, M., Jamali, R., Arj, A., Matini, S. M., Moraveji, A., & Taherkhani, E. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9270 · Cited by 59
The protective effect and underlying mechanism of metformin on neointima formation in fructose-induced insulin resistant rats
Lü, J., Ji, J., Meng, H., Wang, D., Jiang, B., Liu, L., Randell, E. W., Adeli, K., & Meng, Q. H. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-58 · Cited by 56
Metformin-clinical pharmacology in PCOs.
Dumitrescu, R., Mehedințu, C., Briceag, I., Purcărea, V. L., & Hudita, D. (2015) · PubMed · Cited by 62
Effective interventions in preventing gestational diabetes mellitus: A systematic review and meta-analysis
Takele, W. W., Vesco, K. K., Josefson, J., Redman, L. M., Hannah, W., Bonham, M. P., Chen, M., Chivers, S. C., Fawcett, A. J., Grieger, J. A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00491-1 · Cited by 55
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58
Current strategies for the inhibition of hepatic glucose production in type 2 diabetes
Dale, S. E. (2009) · Frontiers in bioscience · doi:10.2741/3301 · Cited by 55
Repurposing Drugs to Target the Diabetes Epidemic
Turner, N. A., Zeng, X., Osborne, B., Rogers, S., & Ye, J.-M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.01.007 · Cited by 59
Metformin, lipids and atherosclerosis prevention
Jenkins, A. J., Welsh, P. I., & Petrie, J. R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000532 · Cited by 55
Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin‐sensitizing agents
Home, P. D., & Pacini, G. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00761.x · Cited by 55
Low Utilization of Circulating Glucose after Food Withdrawal in Snell Dwarf Mice
Brooks, N. L., Trent, C. M., Raetzsch, C. F., Flurkey, K., Boysen, G., Perfetti, M. T., Jeong, Y.-C., Klebanov, S., Patel, K. B., Khodush, V. R., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700484200 · Cited by 51
Metformin and pioglitazone: effectively treating insulin resistance
Staels, B. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112732 · Cited by 51
Metformin: A Narrative Review of Its Potential Benefits for Cardiovascular Disease, Cancer and Dementia
Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 51
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 50

Authors: Natali, A., & Ferrannini, E.
Affiliations: University of Pisa (IT)
Corresponding author: Ferrannini, E.
ORCID: Natali, A.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2006-02-14
Volume: 49
Issue: 3
Pages: 434-441
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-006-0141-7
OpenAlex: W2123472586
Cited by: 377
References: 32
Citations by year: 2026: 4 · 2025: 12 · 2024: 5 · 2023: 27 · 2022: 24 · 2021: 27 · 2020: 23 · 2019: 22 · 2018: 25 · 2017: 23 · 2016: 20 · 2015: 20 · 2014: 13 · 2013: 27 · 2012: 17
FWCI: 2.79
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: metformin, thiazolidinediones, type 2 diabetes, hepatic glucose production, insulin resistance, glucose uptake, insulin sensitivity, glucose clearance, peroxisome proliferator-activated receptor gamma agonists, insulin-stimulated glucose disposal
MeSH terms: Animals, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glucose, Humans, Liver, Metformin, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks